Bildkälla: Stockfoto

Egetis Therapeutics: Additional comment on financing - Redeye

Redeye provides an additional comment on the news that Egetis Therapeutics has secured in total SEK462m in funding, including SEK172m from a directed issue/private placement. We see this as a significant de-risk and argue that the positive reaction in the share price is warranted given the low expectations baked into today’s valuation.

Redeye provides an additional comment on the news that Egetis Therapeutics has secured in total SEK462m in funding, including SEK172m from a directed issue/private placement. We see this as a significant de-risk and argue that the positive reaction in the share price is warranted given the low expectations baked into today’s valuation.
Börsvärldens nyhetsbrev
ANNONSER